Sonova Holding AG (PHBA) Stock Price & Analysis
PHBA Stock Chart & Stats
- Day’s Range
- EUR 59.50 - EUR 59.50
- 52-Week Range
- EUR 35.20 - EUR 60.50
- Previous Close
- EUR 60.00
- Volume
- N/A
- Average Volume (3M)
- 1
- Market Cap
- EUR 17.73B
- Enterprise Value
- EUR 14.53B
- Total Cash (Recent Filing)
- EUR 722.10M
- Total Debt (Recent Filing)
- EUR 1.71B
- Price to Earnings (P/E)
- 39.3
- Beta
- 0.87
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- 0.98
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.65%
Bulls Say, Bears Say
Bulls Say
High-margin Business Model
Persistently high gross and EBITDA margins indicate differentiated products, pricing power, and an attractive business mix. This profitability provides room to fund innovation, retail expansion, and shareholder returns while supporting resilience through normal demand fluctuations.
Product Innovation And Share Gains
Successful launches are translating innovation into measurable market-share gains, supporting a durable competitive position in hearing instruments. AI-enabled products and Virto R also expand upgrade opportunities and can sustain growth through differentiated functionality.
Strong Cash Generation
High cash conversion and improved leverage give Sonova internal funding capacity for product development, store expansion, and selective acquisitions. Strong returns on capital also indicate that growth investments are currently producing attractive economic output.
Bears Say
Cochlear Implant Weakness
The cochlear implant business is experiencing material volume and profit pressure, reducing diversification benefits and weighing on group earnings. Recovery depends partly on a new processor launch, leaving execution and product adoption important to near-term performance.
China And Regulatory Pressure
Value-Based Procurement can pressure pricing and access, while competitor launches may weaken Sonova’s position in China’s implant market. These forces could persist beyond a single quarter and make the planned cochlear implant recovery more difficult.
Top-line And Margin Compression
Recent revenue contraction and lower net margins show that strong underlying profitability has not fully prevented earnings pressure. If growth remains uneven, reduced operating leverage could constrain reinvestment capacity and make future profit expansion less predictable.
Sonova Holding AG News
PHBA FAQ
What was Sonova Holding AG’s price range in the past 12 months?
What is Sonova Holding AG’s market cap?
When is Sonova Holding AG’s upcoming earnings report date?
How were Sonova Holding AG’s earnings last quarter?
Is Sonova Holding AG overvalued?
Does Sonova Holding AG pay dividends?
What is Sonova Holding AG’s EPS estimate?
How many shares outstanding does Sonova Holding AG have?
What happened to Sonova Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sonova Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Sonova Holding AG Stock Smart Score
Company Description
Sonova Holding AG
Sonova Holding AG is a prominent developer, manufacturer, and global distributor of hearing health solutions for all age groups. The company's operations are divided into two core areas: Hearing Instruments and Cochlear Implants. Its product range includes sophisticated wireless communication devices, innovative rechargeable hearing aids, and a comprehensive selection of consumer audio electronics such as wireless headsets, hearables designed for speech enhancement, high-fidelity headphones, microphones, and wireless transmission systems. Furthermore, Sonova offers extensive audiological care services. Key brands under its umbrella include Phonak, Unitron, and Hansaton for hearing instruments; Advanced Bionics for cochlear implants; and Sennheiser for consumer audio. Its audiological care services are delivered through a vast network of approximately 3,600 retail locations and clinics, known by various regional names including AudioNova, Audium, and Connect Hearing. Sonova distributes its products through independent partners and provides services via its direct network. The company maintains a significant international presence, operating in the United States, Europe, the Middle East, Africa, and the Asia Pacific region. Established in Stäfa, Switzerland, in 1947, the firm was formerly known as Phonak Holding AG before adopting its current name, Sonova Holding AG, in August 2007.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Eric Alain Bernard
- Employees
- 18,447
- Website
- www.sonova.com
- Address
- Laubisrutistrasse 28, Stäfa, ZH, 8712, CH
Sonova Holding AG (PHBA) Earnings & Revenues
PHBA Earnings Call
Earnings Call SentimentPositive
The call highlights strong product-led sales momentum (notably in wholesale and select APAC markets), meaningful operating leverage, high cash conversion and disciplined capital allocation. Key short-term challenges are concentrated in the Cochlear Implants business (notably China) and several non‑core one-off charges plus FX headwinds. Management provided a confident but execution‑sensitive midterm roadmap (innovation, multi-channel expansion, operational savings) and reiterated growth and margin guidance for FY26/27.
View all DE:PHBA earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 4 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 10 | 0 | 2 |
